Pulo Pharmaceutical Unit Receives NMPA Approval for Fuzeresai API

Pulo Pharmaceutical announced on August 5, 2026, that its wholly owned subsidiary, Zhejiang Pulo Jiayuan Pharmaceutical Co. , Ltd. , recently received the Chemical Drug Marketing Application Approval Notice for the active pharmaceutical ingredient Fuzeresai, issued by the National Medical Products Administration. The approval notice marks the formal approval of the marketing application for the drug substance.